Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 1901348.
- Also identified by PMC identifier 1014299.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Three patients with acute Guillain-Barré syndrome were treated early in the course of the disease with OKT3, an anti-T-cell monoclonal antibody. Each patient developed acute lymphopenia with specific depletion of T3-positive lymphocytes. Two patients had continued progression of clinical deficits for eight and 14 days. This suggests that T lymphocytes may not be essential for progression of Guillain-Barré syndrome at this stage of the disease.
Medical subject headings
- Antibodies, Monoclonal
- Immunosuppression Therapy
- Polyradiculoneuropathy
- T-Lymphocytes